chiew
2021-07-20
Haiz
Pharma company's stock plunges 70% after bad news from FDA
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
2
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":178008600,"tweetId":"178008600","gmtCreate":1626769764900,"gmtModify":1633771209962,"author":{"id":3566850909705069,"idStr":"3566850909705069","authorId":3566850909705069,"authorIdStr":"3566850909705069","name":"chiew","avatar":"https://static.tigerbbs.com/6a955817d8518ffedcf0489868ef4a98","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":19,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Haiz</p></body></html>","htmlText":"<html><head></head><body><p>Haiz</p></body></html>","text":"Haiz","highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/178008600","repostId":2152178652,"repostType":4,"repost":{"id":"2152178652","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1626769440,"share":"https://www.laohu8.com/m/news/2152178652?lang=&edition=full","pubTime":"2021-07-20 16:24","market":"us","language":"en","title":"Pharma company's stock plunges 70% after bad news from FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2152178652","media":"Dow Jones","summary":"Shares in Ardelyx Inc. (ARDX) plummeted nearly 70% in premarket trading Tuesday, following the bioph","content":"<p>Shares in <a href=\"https://laohu8.com/S/ARDX\">Ardelyx</a> Inc. (ARDX) plummeted nearly 70% in premarket trading Tuesday, following the biopharmaceutical company's announcement that the Food and Drug Administration appears unlikely to approve a drug for dialysis patients. </p>\n<p><img src=\"https://static.tigerbbs.com/17a0b44c44b7dc799f2a035011502f3b\" tg-width=\"709\" tg-height=\"547\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>Ardelyx revealed that it received a letter from the FDA stating that deficiencies in the information provided had been found that would preclude discussion of approvals Ardelyx has sought. </p>\n<p>When Ardelyx sought a meeting with the FDA to discuss the deficiencies, the request was denied, though Ardelyx stated that \"the FDA noted that a key issue is the size of the treatment effect and its clinical relevance.\" </p>\n<p>\"This is an extremely disheartening and disappointing communication from the FDA, particularly following the weeks of label discussions that occurred in early April, the fact that our NDA submission included three pivotal trials across 1,000 patients, all which met their primary and key secondary endpoints, as well as the additional data analyses we submitted in late April in response to the FDA's requests,\" Ardelyx Chief Executive Mike Raab said in a statement. </p>\n<p>Ardelyx shares, which closed at $7.70 in the regular session for a market capitalization of more than $700 million, saw shares dive to less than $2.50 in the after-hours trading period.</p>\n<p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pharma company's stock plunges 70% after bad news from FDA</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPharma company's stock plunges 70% after bad news from FDA\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-07-20 16:24</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares in <a href=\"https://laohu8.com/S/ARDX\">Ardelyx</a> Inc. (ARDX) plummeted nearly 70% in premarket trading Tuesday, following the biopharmaceutical company's announcement that the Food and Drug Administration appears unlikely to approve a drug for dialysis patients. </p>\n<p><img src=\"https://static.tigerbbs.com/17a0b44c44b7dc799f2a035011502f3b\" tg-width=\"709\" tg-height=\"547\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>Ardelyx revealed that it received a letter from the FDA stating that deficiencies in the information provided had been found that would preclude discussion of approvals Ardelyx has sought. </p>\n<p>When Ardelyx sought a meeting with the FDA to discuss the deficiencies, the request was denied, though Ardelyx stated that \"the FDA noted that a key issue is the size of the treatment effect and its clinical relevance.\" </p>\n<p>\"This is an extremely disheartening and disappointing communication from the FDA, particularly following the weeks of label discussions that occurred in early April, the fact that our NDA submission included three pivotal trials across 1,000 patients, all which met their primary and key secondary endpoints, as well as the additional data analyses we submitted in late April in response to the FDA's requests,\" Ardelyx Chief Executive Mike Raab said in a statement. </p>\n<p>Ardelyx shares, which closed at $7.70 in the regular session for a market capitalization of more than $700 million, saw shares dive to less than $2.50 in the after-hours trading period.</p>\n<p></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ARDX":"Ardelyx"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2152178652","content_text":"Shares in Ardelyx Inc. (ARDX) plummeted nearly 70% in premarket trading Tuesday, following the biopharmaceutical company's announcement that the Food and Drug Administration appears unlikely to approve a drug for dialysis patients. \n\nArdelyx revealed that it received a letter from the FDA stating that deficiencies in the information provided had been found that would preclude discussion of approvals Ardelyx has sought. \nWhen Ardelyx sought a meeting with the FDA to discuss the deficiencies, the request was denied, though Ardelyx stated that \"the FDA noted that a key issue is the size of the treatment effect and its clinical relevance.\" \n\"This is an extremely disheartening and disappointing communication from the FDA, particularly following the weeks of label discussions that occurred in early April, the fact that our NDA submission included three pivotal trials across 1,000 patients, all which met their primary and key secondary endpoints, as well as the additional data analyses we submitted in late April in response to the FDA's requests,\" Ardelyx Chief Executive Mike Raab said in a statement. \nArdelyx shares, which closed at $7.70 in the regular session for a market capitalization of more than $700 million, saw shares dive to less than $2.50 in the after-hours trading period.","news_type":1},"isVote":1,"tweetType":1,"viewCount":259,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":4,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/178008600"}
精彩评论